SKYE (Skye Bioscience, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SKYE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | 5AM CO-INVESTORS II LP | 10%+ Owner | Sell | — | — |
| 2026-08-20 | Andrew J. Schwab | Director | Sell | — | — |
| 2026-08-07 | PUNIT DHILLON | Chief Executive Officer | A | — | — |
| 2026-08-07 | PUNIT DHILLON | Chief Executive Officer | A | — | — |
| 2026-04-02 | Paul A. Grayson | Director | A | — | — |
| 2026-04-02 | Deborah H. Charych | Director | A | — | — |
| 2026-04-02 | Andrew J. Schwab | Director | A | — | — |
| 2026-04-02 | Karen L. Smith | Director | A | — | — |
| 2026-04-02 | Tuan Tu Diep | Chief Operating Officer | MIXED | — | — |
| 2026-04-02 | Annalisa Jenkins | Director | A | — | — |
| 2026-04-02 | Christopher Twitty | Chief Scientific Officer | MIXED | — | — |
| 2026-04-02 | PUNIT DHILLON | Chief Executive Officer | MIXED | — | — |
| 2026-02-09 | Christopher Twitty | Chief Scientific Officer | A | — | — |
| 2026-02-09 | Paul A. Grayson | Director | A | — | — |
| 2026-02-09 | Tuan Tu Diep | Chief Development Officer | A | — | — |
| 2026-02-09 | Puneet S. Arora | Chief Medical Officer | A | — | — |
| 2026-02-09 | Andrew J. Schwab | Director | A | — | — |
| 2026-02-09 | PUNIT DHILLON | Chief Executive Officer | A | — | — |
| 2026-02-09 | Annalisa Jenkins | Director | A | — | — |
| 2026-02-09 | Deborah H. Charych | Director | A | — | — |
| 2026-02-09 | Karen L. Smith | Director | A | — | — |
| 2026-02-09 | KAITLYN ARSENAULT | Chief Financial Officer | A | — | — |
| 2025-08-22 | Andrew J. Schwab | Director | Sell | — | — |
| 2025-08-22 | 5AM Ventures VII, L.P. | 10%+ Owner | Sell | — | — |
| 2025-02-28 | KAITLYN ARSENAULT | Chief Financial Officer | Sell | — | — |
| 2025-02-26 | Karen L. Smith | Director | A | — | — |
| 2025-02-26 | Andrew J. Schwab | Director | A | — | — |
| 2025-02-26 | Tuan Tu Diep | Chief Development Officer | A | — | — |
| 2025-02-26 | Paul A. Grayson | Director | A | — | — |
| 2025-02-26 | Annalisa Jenkins | Director | A | — | — |
| 2025-02-26 | Deborah H. Charych | Director | A | — | — |
| 2025-02-26 | Puneet S. Arora | Chief Medical Officer | A | — | — |
| 2025-02-26 | KAITLYN ARSENAULT | Chief Financial Officer | A | — | — |
| 2025-02-26 | PUNIT DHILLON | Chief Executive Officer | A | — | — |
| 2024-11-20 | Tuan Tu Diep | Chief Development Officer | Sell | — | — |
| 2024-11-19 | PUNIT DHILLON | Chief Executive Officer | Sell | — | — |
| 2024-11-19 | Paul A. Grayson | Director | Sell | — | — |
| 2024-11-19 | KAITLYN ARSENAULT | Chief Financial Officer | Sell | — | — |
| 2024-10-30 | KAITLYN ARSENAULT | Chief Financial Officer | A | — | — |
| 2024-10-30 | Deborah H. Charych | Director | A | — | — |
| 2024-10-30 | Karen L. Smith | Director | A | — | — |
| 2024-10-30 | Andrew J. Schwab | Director | A | — | — |
| 2024-10-30 | PUNIT DHILLON | Chief Executive Officer | A | — | — |
| 2024-10-30 | Annalisa Jenkins | Director | A | — | — |
| 2024-10-30 | Paul A. Grayson | Director | A | — | — |
| 2024-10-30 | Tuan Tu Diep | Chief Development Officer | A | — | — |
| 2024-09-13 | Andrew J. Schwab | Director | Sell | — | — |
| 2024-09-13 | 5AM Ventures II LP | 10%+ Owner | Sell | — | — |
| 2024-09-04 | Puneet S. Arora | Chief Medical Officer | A | — | — |
| 2024-08-27 | PUNIT DHILLON | Chief Executive Officer | J | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 202,630 | — |
| — | Chief Executive Officer | 178,646 | — |
| — | 10%+ Owner | 175,070 | — |
| — | Director | 43,243 | — |
| — | Chief Financial Officer | 26,318 | — |
| — | Chief Operating Officer | 10,282 | — |
| — | 10%+ Owner | 8,285 | — |
| — | Director | 6,901 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SKYE quote page; the site-wide leaderboard is on the insider transactions hub.